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In this issue ofCell Host &Microbe, Siegel et al. (2014) report that colonization of Streptococcus pneumoniae
is facilitated by coinfection with influenza virus through utilization of sialic acids cleaved by the viral neur-
aminidase. The implications of this finding for use of influenza antivirals to prevent flu-related complications
are discussed.Study of the ecology of microbes offers
several examples of metabiosis, a rela-
tionship whereby one organism creates
conditions favorable for a second, unre-
lated organism. None may be more
important to the public health than the
advantages gained by Streptococcus
pneumoniae in the presence of influenza
viruses. In this issue, Siegel et al. answer
a long-standing question about the
two pathogens’ metabiotic relationship
by defining the mechanism through which
influenza viruses enhance pneumococcal
colonization (Siegel et al., 2014). The influ-
enza virus neuraminidase, through its
enzymatic activity, which cleaves terminal
sialic acids found abundantly on epithelial
surfaces and enriches the mucin pool
in the nasopharynx, provides a carbon
source that pneumococci can catabolize
to enable rapid growth. The individual ele-
ments of the findings of Siegel et al. have
been appreciated in the field previously
(McCullers, 2014); here, the authors of
this work weave these various pieces
into a whole tapestry through a series
of elegant experiments that define a new
mechanism for viral-bacterial copatho-
genesis (Siegel et al., 2014). Increased
bacterial growth in the presence of virus
is shown to be dependent on both the
increased availability of sialic acids in the
nasopharynx during viral infection and
the ability of the bacteria to catabolize
these sugars as substrate. Thus, as a
side effect of the natural life cycle of influ-
enza viruses, bacterial replication and
colonization are favored. The enhanced
colonization density is also shown to be
associated with increased aspiration into
the lungs, a first step toward develop-
ment of pneumonia, and presumably
also contributes to increased transmis-sion between hosts as has been observed
in animal models and community studies.
This biologically interesting mechanism
is alsomedically important. As pneumonia
is the leading killer of children worldwide,
much of the morbidity and mortality asso-
ciated with influenza pneumonia stems
from synergistic interactions with coin-
fecting bacteria, and colonization is typi-
cally regarded as a first step toward devel-
opment of pneumonia (McCullers, 2014).
Importantly, the implications of this finding
likely extend beyond the influenza-pneu-
mococcus pair, since other bacterial
species that can opportunistically cause
pneumonia, including Staphylococcus
aureus and Haemophilus influenzae, are
also able to utilize sialic acids as a cata-
bolic substrate. Therefore, one might
expect similar findings if colonization
with another bacterial species were stud-
ied in the context of viral coinfection. The
potential impact of this on public health
may include more than just the increased
risk of pneumonia. If viruses are facilita-
ting colonization and transmission of, for
example, methicillin-resistant S. aureus
(MRSA) through this mechanism, a multi-
tude of disease states that can poten-
tially follow acquisition and colonization
of these deadly bacteria in susceptible
or compromised hosts may be affected.
With the continued and accelerating
emergence of antimicrobial resistance,
factors that facilitate spread or promote
survival of such organisms are likely to
carry a significant economic cost. Cata-
bolic pathways involved in sialic acid utili-
zation therefore may be viable targets for
development of therapeutics or vaccines
against such pathogens.
Other respiratory viruses including the
parainfluenzaviruses express a sialidaseCell Host & Micand can facilitate bacterial pneumonia.
This suggests a broader importance for
the outlined metabiotic mechanism in
the pathogenesis of viral respiratory tract
infections. A recent study from Grijalva
et al. reinforces this idea bydemonstrating
that influenza viruses and parainfluenza-
viruses, which possess neuraminidases,
enhance acquisition of pneumococcal
colonization in young children while other
viruses do not (Grijalva et al., 2014). As is
seen with influenza viruses, inhibition of
the viral neuraminidase of paramyxovi-
ruses through small molecule approaches
in animal models diminishes the impact of
viral infection on secondary bacterial dis-
ease (Alymova et al., 2005). Importantly,
the beneficial effects of neuraminidase
inhibitors on secondary bacterial pneu-
monia in animal models and in some hu-
man studies extend beyond the window
where they are able to directly impact viral
load (McCullers, 2004; Fry et al., 2014). A
combination of animal and human studies
suggest that the impact of neuraminidase
inhibitors on viral replication and on symp-
toms directly attributable to the virus
is greatest following initiation of treat-
ment within the first 48 hours of the
viral infectionbeingestablished.However,
the benefit of neuraminidase inhibitors
against bacterial superinfections and
other complications of influenza may
extend beyond the initial infection window
and last up to 5 days or longer (McCullers,
2004;Muthuri et al., 2014; Fry et al., 2014).
It is likely the ‘‘off-target’’ effects of sialic
acid cleavage that are inhibited by antivi-
rals in this medically relevant scenario,
including the metabiosis engendered by
this mechanism. Indeed, the presence of
virus in the study from Siegel et al. was
associated with increased free and totalrobe 16, July 9, 2014 ª2014 Elsevier Inc. 3
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cins late in infection peaking at day 7,
and the competitive disadvantage medi-
ated by loss of the ability to catabolize
sialic acids increased over 7 days of colo-
nization (Siegel et al., 2014). Even though
viral replication is not reduced by delayed
antiviral treatment, the impact of ongoing
viral neuraminidase activity on making
sialic acids available as catabolic sub-
strates for S. pneumoniae may be dimin-
ished by late therapy.
The potential ability of neuraminidase
inhibitors to impact secondary bacterial
disease and to retain beneficial effects
beyond the 48 hr window where they
are most effective against virus-induced
symptoms has important public health
policy implications. The primary efficacy
studies of the neuraminidase inhibitors
zanamivir and oseltamivir were designed
using endpoints relevant to achieving
approval by the Food and Drug Admin-
istration and other licensing bodies.
These studies were typically carried out
in healthy adults and used the reduction
in symptoms as clinical endpoints and
reduction in viral titer as virologic end-
points. The overall utility of these drugs
for combating influenza has been ques-
tioned recently in a secondary analysis
that was restricted in scope to select ran-
domized controlled trials of efficacy and
used ‘‘time to first alleviation of symp-
toms’’ as a primary endpoint (Jefferson
et al., 2014). The authors concluded that
treatment effects were modest and the4 Cell Host & Microbe 16, July 9, 2014 ª2014‘‘trade-off between benefits and harms
should be borne in mind when making de-
cisions to use oseltamivir for treatment,
prophylaxis, or stockpiling.’’ This report
and related opinion pieces have led
some to conclude that antiviral treatment
of influenza may not be beneficial and
have prompted media reports suggesting
the drugs are ‘‘useless’’ and ‘‘ineffective,’’
damaging the public trust in anti-influenza
therapy (Butler, 2014). However, these an-
alyses focus narrowly on only one type
of study and thus fail to appropriately
consider the potentially broader benefits
beyond symptom reduction, since the pri-
mary efficacy studies were not designed
to address other outcomes directly. There
is a strongbodyof evidence fromobserva-
tional studies that supports a view that the
neuraminidase inhibitors are effective in
preventing or ameliorating many of the
severe and/or economically important
complications of influenza including otitis
media, admission to the hospital, influ-
enza pneumonia, and death (Fry, 2014).
The work of Siegel et al. provides a new
biologic rationale for the utility of antivirals
that inhibit sialidase activity in preventing
these influenza-related complications
(Siegel et al., 2014) and support a view
that the decision to initiate therapy should
be informed by more than just a desire to
limit symptoms of the flu. Use of these
drugs is likely to decrease subsequent
important and costly complications—and
may provide an unanticipated societal
benefit by reducing colonization densityElsevier Inc.and transmission of medically important
and (potentially) antimicrobial resistant
pathogens. Although initiation of therapy
early in the course of disease is likely to
have the strongest impact, data from this
study and others suggests that late treat-
ment should also be considered in clinical
practice and in trial design.
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